Updated segment financials reflect transfer of Ophthalmic Pharmaceuticals franchise from Alcon to Pharmaceuticals, and 19 mature products from Pharmaceuticals to Sandoz, as outlined in Q4 and FY 2015 earnings releaseNo change in audited 2015 Consolidat…
New research published today in a report from the IMS Institute for Healthcare Informatics – Delivering on the Potential of Biosimilar Medicines: The Role of Functioning Competitive Markets, highlights the opportunity for biosimilars to create savings …
Medicines for Europe is the new name of EGA (European Generic and Biosimilar Medicines Association) as of today. Representing the pharmaceutical companies supplying the largest share of medicines across Europe, Medicines for Europe is the voice of the …
Novartis Access is a first-of-its-kind portfolio of products aimed at increasing access to medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer in low- and low-middle-income countriesFirst Novartis Access shipmen…
Holzkirchen, 25 February, 2016 – Sandoz, a Novartis company and the global leader in biosimilars, announced today that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a type II variation for the addition of a s…
Holzkirchen, February 15, 2016 – Sandoz, together with leading global charity World Child Cancer (WCC), is pleased to announce a new health initiative in the Philippines, aimed at improving the standard of care for children suffering from cancer.Cancer…
Holzkirchen, February 15, 2016 – Sandoz, together with leading global charity World Child Cancer (WCC), is pleased to announce a new health initiative in the Philippines, aimed at improving the standard of care for children suffering from cancer.Cancer…
Sandoz acquires rights to PF-06438179 (biosimilar infliximab) in the European Economic Area (EEA)*Sandoz plans to complete Phase III development program and file for registration in the EUDeal strengthens Novartis immunology portfolio which includes in…
Sandoz’ late-stage biosimilar pipeline gains momentum with sustained investment – five of 10 planned regulatory filings achievedSandoz believes that the totality of evidence in its submission, including three pivotal clinical studies, demonstrates that…
Sandoz’ late-stage biosimilar pipeline gains momentum with sustained investment – five of 10 planned regulatory filings achievedSandoz believes that the totality of evidence in its submission, including three pivotal clinical studies, demonstrates that…